New Cancer Drug Combination Significantly Delays Breast Cancer Progression
9/26/2011
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) - an antibody-guided drug - for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening...
Onset Of Metastases Delayed In Hormone-Resistant Prostate Cancer
9/26/2011
Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher told the 2011 European Multidisciplinary Cancer Congress [1]...
2 New Cost-Effective Ways To Predict Prostate Cancer
9/26/2011
Two new risk indicators for prostate cancer were unveiled at the 2011 European Multidisciplinary Cancer Congress. Led by Dr David Orsted at the Copenhagen University Hospital, Herlev, the first study shows that men diagnosed with benign prostate enlargement have an increased risk of developing and dying from prostate cancer...
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported at the 2011 European Multidisciplinary Cancer Congress. Dr...
Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year...
Study Hopes To Standardize Clinical Practice Across Europe For The Treatment Of Rectal Cancer
9/26/2011
First results from an international comparison of the care of patients with rectal cancer have shown there are substantial differences in the use of chemotherapy and radiotherapy between European countries...
Synchronous Chemoradiation Reduces Risk Of Breast Cancer Recurrence
9/26/2011
A major UK trial has produced firm evidence that giving radiotherapy between or during chemotherapy cycles to women with early breast cancer significantly reduces the risk of the cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on the patients' quality of life...
A study supported by the U.S. Department of Health and Human Services could not validate or confirm previous research findings that suggested the presence of one of several viruses in blood samples of people living with chronic fatigue syndrome. The new study also could not find the viruses in blood samples of healthy donors who were previously known to not have the viruses...
Afinitor (Everolimus) Prolongs Advanced Breast Cancer Patients' Progression Free Survival Time
9/26/2011
Afinitor (evelolimus), a Novartis kidney cancer drug, when combined with hormonal therapy doubled breast cancer patients' progression-free survival, and reduced cancer progression risk by 57% compared to exemestane alone, researchers revealed during a Presidential Symposium at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden...
Rectal Cancer Treatment Varies Greatly From Country To Country, Europe
9/25/2011
Chemotherapy and radiotherapy usage for rectal cancer varies greatly from nation-to-nation within Europe, researchers from Leiden University Medical Centre, the Netherlands, reported at the European Multidisciplinary Cancer Congress 2011, Stockholm, Sweden. The presenters said that clinical practice across Europe needs to become standardized...